JP2022543391A5 - - Google Patents

Info

Publication number
JP2022543391A5
JP2022543391A5 JP2022506639A JP2022506639A JP2022543391A5 JP 2022543391 A5 JP2022543391 A5 JP 2022543391A5 JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022543391 A5 JP2022543391 A5 JP 2022543391A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022506639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044733 external-priority patent/WO2021026066A1/en
Publication of JP2022543391A publication Critical patent/JP2022543391A/ja
Publication of JP2022543391A5 publication Critical patent/JP2022543391A5/ja
Priority to JP2026003598A priority Critical patent/JP2026063085A/ja
Withdrawn legal-status Critical Current

Links

JP2022506639A 2019-08-05 2020-08-03 トロフィネチドの組成物 Withdrawn JP2022543391A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026003598A JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
US62/882,998 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026003598A Division JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Publications (2)

Publication Number Publication Date
JP2022543391A JP2022543391A (ja) 2022-10-12
JP2022543391A5 true JP2022543391A5 (enExample) 2023-08-15

Family

ID=74502416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506639A Withdrawn JP2022543391A (ja) 2019-08-05 2020-08-03 トロフィネチドの組成物
JP2026003598A Pending JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026003598A Pending JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Country Status (16)

Country Link
US (3) US11370755B2 (enExample)
EP (1) EP4009962A4 (enExample)
JP (2) JP2022543391A (enExample)
KR (1) KR20220059479A (enExample)
CN (1) CN114667136A (enExample)
AU (1) AU2020324396B2 (enExample)
BR (1) BR112022002229A2 (enExample)
CA (1) CA3149633A1 (enExample)
CL (1) CL2022000301A1 (enExample)
CO (1) CO2022002616A2 (enExample)
IL (1) IL290324A (enExample)
JO (1) JOP20220027A1 (enExample)
MX (1) MX2022001505A (enExample)
MY (1) MY206115A (enExample)
SA (1) SA522431585B1 (enExample)
WO (1) WO2021026066A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667136A (zh) 2019-08-05 2022-06-24 诺仁制药有限公司 Trofinetide的组合物
US11827600B2 (en) * 2021-07-12 2023-11-28 Acadia Pharmaceuticals Inc. Crystalline forms of trofinetide
WO2025169163A1 (en) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Method for the synthesis of trofinetide and its analogues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573765B1 (fr) * 1984-11-23 1988-06-10 Solvay Procede pour la synthese de peptides
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
WO2007106555A2 (en) 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
EP2060580A1 (en) * 2007-11-19 2009-05-20 SOLVAY (Société Anonyme) Process for the manufacture of persilylated peptides
SI2667715T1 (sl) * 2011-01-27 2017-11-30 Neuren Pharmaceuticals Limited Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
CN114667136A (zh) * 2019-08-05 2022-06-24 诺仁制药有限公司 Trofinetide的组合物

Similar Documents

Publication Publication Date Title
JP2021184963A5 (enExample)
JP2023171775A5 (enExample)
JP2022184985A5 (enExample)
JP2023103258A5 (enExample)
JP2023166402A5 (enExample)
JP2023518821A5 (enExample)
JP2023145572A5 (enExample)
JP2022541332A5 (enExample)
JP2022543046A5 (enExample)
JP2022028828A5 (enExample)
JP2022025124A5 (enExample)
JP2025511899A5 (enExample)
JP2023514727A5 (enExample)
JP2021185136A5 (enExample)
JP2022538797A5 (enExample)
JP2023552816A5 (enExample)
JP2021038271A5 (enExample)
JP2023181322A5 (enExample)
JPWO2020148954A5 (enExample)
JP2024045126A5 (enExample)
JP2020171301A5 (enExample)
JP2022537813A5 (enExample)
JP2020120660A5 (enExample)
JP2023093656A5 (enExample)
JP2023078173A5 (enExample)